Moderna Cancer Vaccine Hits Phase 3 Endpoint; "AI Cures Cancer" Hype Debunked

Merck and Moderna announced that their personalized mRNA cancer therapy mRNA-4157 (Intismeran) combined with Keytruda met its primary endpoint in a Phase 3 trial of 1,137 post-surgery high-risk melanoma patients, significantly extending recurrence-free and distant metastasis-free survival. Viral claims of "AI inventing a cancer vaccine overnight" were quickly debunked by scholars. The verdict: real and important science, but a badly exaggerated AI narrative.

Confirmed

Why it matters

2026-08-20 ~ 2026-08-20 · 7 related posts

Full story(4 episodes)→

Primary sources